RE:RE:RE:RE:RE:New office posted on website the way you would interpret anything...so far is nothing bu5 doom & gloom.
so why are you here.
obviously working hard as a FUDster.
admittedly , Onc has not hsd any new news since the good reults out the anal cancer trial with Roche.
New office in the USA means as a minimum they intend to have a continued legal existence in the USA.
Beyond that?
A company I owned that was bought out, spent a lot of $$ on new signage in a large frontage high profile building in Toronto.
The sign could be seen from a Toronto airport.
They were bought out within 6 months of that sign.
point being. Until a company is aquired, it is business as usual.
ONC has prudently negotiated a lease costing less. Somehow Mr Emneo, turns that into a bad thing.
And absolutely they could be aquired. There might be lease conditions & commitments. All small change relative to getting Pelareorep to market.
Quite frankly , I was more concerned when they did not have lease indications.
Buyout opportunities?
The location of offices, employees wages erc. Nothing to do with the decision.
oncokytics biotech will or will not be bought out based on the potential market fo4 Pelareorep.
so far... results from co- therapy with a Roche , being th3 Pancreatic cancer , phase 3 FDA fast track approval.
The most recent anal cancer results and previous trials, things are looking up.
Most important question. They intend to enrol first patient in the Pancreatic phase 3 mid of this year.
Thst needs a lot of $$$.
parterdhip?
buyout?
other business arrangement?
Those details are needed. Soon.